Application of F-circP3F / miR-326 / GLI1 / PI3K-AKT-mTOR axis in diagnosis and treatment of rhabdomyosarcoma

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By elucidating the signal regulation mechanism of the F-circP3F/miR-326/GLI1/PI3K-AKT-mTOR axis, and utilizing a combined treatment strategy of F-circP3F inhibitors and PI3K inhibitors, the diagnostic and treatment challenges of ARMS have been solved, and effective inhibition of ARMS has been achieved.

CN122097582APending Publication Date: 2026-05-29BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY

3 Cites 0 Cited by

Patent Information

Application Number: CN202610129915.5
Authority / Receiving Office: CN · China
Patent Type: Applications(China)
Current Assignee / Owner
Filing Date: 2026-01-30
Publication Date: 2026-05-29

Application Information

Patent Timeline

30 Jan 2026

Application

CN202610129915.5

29 May 2026

Publication

CN122097582A

IPC: A61K45/00; A61P35/00; A61P21/00; A61K45/06; A61K31/5377; A61K31/506; C12N15/113; C12Q1/6886; G01N33/573; G01N33/575

CPC: A61K45/00; A61P35/00; A61P21/00; A61K45/06; A61K31/5377; A61K31/506; C12N15/113; C12Q1/6886

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

The existing technology lacks sufficient understanding of the ceRNA regulatory mechanism of PAX3-FOXO1-related circRNAs in rhabdomyosarcoma, resulting in a lack of effective means for the diagnosis and treatment of ARMS.

Method used

The signal regulation mechanism of the F-circP3F/miR-326/GLI1/PI3K-AKT-mTOR axis was revealed. ARMS growth was inhibited by using F-circP3F inhibitors, miR-326 promoters, GLI1 inhibitors and PI3K inhibitors, especially the combined application of GANT61 and LY294002.

Benefits of technology

It significantly inhibited ARMS cell proliferation, migration and tumor growth in in vitro and in vivo experiments, providing new diagnostic biomarkers and therapeutic targets, and opening up new avenues for targeted therapy of ARMS.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, in particular to application of an F-circP3F / miR-326 / GLI1 / PI3K-AKT-mTOR axis in diagnosis and treatment of rhabdomyosarcoma. The invention systematically reveals the key effect of F-circP3F and a ceRNA regulation network thereof in the occurrence and development of ARMS for the first time, verifies the treatment strategy of a targeted F-circP3F / miR-326 / GLI1 / PI3K-AKT-mTOR axis, not only provides a new molecular marker for the diagnosis, prognosis evaluation and treatment monitoring of ARMS, but also opens up a new way for the targeted treatment of the disease.

Need to check novelty before this filing date? Find Prior Art